<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01957826</url>
  </required_header>
  <id_info>
    <org_study_id>FIBHGM-ECNC017-2010</org_study_id>
    <secondary_id>2010-024406-35</secondary_id>
    <secondary_id>MIYOCYTE</secondary_id>
    <nct_id>NCT01957826</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy</brief_title>
  <official_title>Phase I/II Randomized Clinical Trial to Assess the Safety and Feasibility of Transendocardial Injection of Bone Marrow Autologous Mesenchymal Stem Cells in Patients With Idiopathic Dilated Cardiomyopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Gregorio Marañon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministerio de Sanidad, Servicios Sociales e Igualdad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, the feasibility and the efficacy of
      transendocardial injection of bone marrow-derived mesenchymal stem cells (MSCs) in patients
      with dilated idiopathic cardiomyopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic congestive heart failure (CHF) is a public health problem that entails high rates of
      morbidity and mortality, and enormous costs for health systems worldwide. In the United
      States there are 5 million people living with CHF, and each year 60.000 people reach terminal
      phases of the disease, with mortality rates of 70-80% at two years. Although the first cause
      of CHF in developed countries is atherosclerotic coronary artery disease (CAD), dilated
      idiopathic cardiomyopathy (DCM) represents almost half of the cases of newly diagnosed CHF.
      Treatment of CHF includes pharmacological and non-pharmacological strategies, including
      implantable cardioverter defibrillators, cardiac resynchronization therapy and heart
      transplantation. Despite all these advances, CHF prognosis remains poor. Cardiac stem cell
      therapy emerged more than ten years ago as a new hope for CHF patients.

      Although the most extensive evidence of the benefits of stem cell therapy for cardiovascular
      diseases refers to ischemic heart disease (CAD), initial experiences with stem cells for
      other conditions such as DCM are encouraging.

      This randomized clinical trial will include 70 patients with DCM, left ventricular ejection
      fraction (LVEF) between 20% and 45%, and who are symptomatic in New York Heart Association
      (NYHA) functional class II-III/IV. In a first-in-man pilot phase, 10 patients will be treated
      with transendocardial injections of bone marrow-derived MSCs after cardiac catheterization
      and NOGA XPTM mapping of the left ventricle. A Data and Safety Monitoring Board (DSMB) will
      analyse the safety and feasibility of this first phase of the trial, and then 60 patients
      more will be randomized to receive MSCs or placebo (ratio 3:1).

      Primary objectives include safety and feasibility variables, and secondary objectives include
      efficacy variables. All patients will be studied with a complete cardiac imaging protocol
      that includes: electrocardiography, echocardiography, treadmill tests with oxygen
      consumption, holter, laboratory analyses, magnetic resonance imaging (MRI), single photon
      emission computed tomography (SPECT), electromechanical mapping (NOGA XPTM) and quality of
      life questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac adverse events. SAEs and AEs.</measure>
    <time_frame>change from enrollment( 1, 3, 6, 12, 18 and 24 months)</time_frame>
    <description>Major adverse cardiac adverse events includes cerebral adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NYHA functional class.</measure>
    <time_frame>Change from enrolment( 1, 3, 6, 12, 18, 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of complications with the use of NOGA XPTM catheters.</measure>
    <time_frame>Change from enrolment( 1, 3, 6, 12, 18, 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory parameters including C-reactive protein an brain natriuretic peptide</measure>
    <time_frame>Change from enrolment( 1, 3, 6, 12, 18, 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>1, 3, 6, 12, 18, 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Max.oxygen consumption(MVO2),functional capacity.</measure>
    <time_frame>6,12,24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaires</measure>
    <time_frame>6,12 and 24 months</time_frame>
    <description>include 36-item Short Form Survey(SF 36) and Minnesota Living UIT Heart Failure questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension. of perfusion defects(MRI/SPECT).</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF, ventricular vol.,wall motion score index(echocard./MRI/SPECT</measure>
    <time_frame>6,12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF(left ventriculogram, electromech. mapping parameters(NOGA XPTM))</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Primary Idiopathic Dilated Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>transendocardial injection of placebo solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bone marrow-derived MSCs injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bone marrow-derived MSCs injection</intervention_name>
    <description>transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.</description>
    <arm_group_label>bone marrow-derived MSCs injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo intervention</intervention_name>
    <description>placebo administration</description>
    <arm_group_label>placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  II-III NYHA functional class, under optimal medical therapy.

          -  LVEF ≥ 20% and ≤ 45% by echocardiography, SPECT or left ventriculogram one month prior
             to enrollment.

          -  Anterior wall thickness ≥ 8 mm by echocardiography or MRI one month prior to
             enrollment.

          -  Idiopathic DCM diagnosis (having excluded CAD, valvular heart disease, cardiac toxic
             drugs, tachyarrhythmias, metabolic diseases, systemic diseases, infectious diseases)
             six months prior to enrollment.

          -  Patients rejected for heart transplantation should have been discussed in the Heart
             Team at their respective centres, and a document stating the reason for exclusion will
             be kept in the medical record.

          -  Able to exercise on a treadmill, MVO2 between ≥ 12 and ≤ 21 ml/Kg/min.

          -  Hemodynamic stability (blood pressure &gt; 100/40 mmHg, heart rate &lt; 110 bpm and oxygen
             saturation &gt; 95%).

          -  Negative pregnancy test in women.

          -  Signed informed consent

        Exclusion Criteria:

          -  Evidence of secondary dilated cardiomyopathy causes: CAD, valvular heart disease,
             cardiac toxic drugs, tachyarrhythmias, metabolic diseases, systemic diseases,
             infectious diseases, myocarditis or postpartum ventricular dysfunction.

          -  Permanent atrial fibrillation.

          -  Candidates for ICD or CRT devices. Patients with theses devices can be enrolled if the
             device has been implanted at least 6 months before inclusion, and only if no-response
             has been observed to CRT.

          -  Candidates for heart transplantation if surgery is anticipated in the next 2 years.

          -  Left ventricular thrombus by echocardiography, MRI or left ventriculogram.

          -  Peripheral artery disease that precludes cardiac catheterization with 8 Fr sheaths. .

          -  Anterior wall thickness &lt; 8 mm by echocardiography or MRI one month prior to
             enrollment.

          -  Chronic renal failure (creatinine &gt; 2,5 mg/dL).

          -  I or IV NYHA functional class. Cardiogenic shock is defined as systolic blood pressure
             &lt; 90 mmHg with no response to fluids, or &lt; 100 mmHg with inotropes and without
             bradycardia.

          -  Previous history of drug abuse (alcohol, etc…).

          -  Acute or chronic infectious disease (including B/C hepatitis and HIV).

          -  Pregnancy or child-bearing period.

          -  MRI contraindications: pacemakers, ICD, metalic prosthesis, etc.

          -  Bleeding or coagulation disorders (INR &gt; 2 without anticoagulation treatment).

          -  Cancer history 5 years prior to enrollment.

          -  Life expectancy less than 1 year.

          -  Any disease or condition that the investigator finds decisive for exclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Fernandez Aviles, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital General Universitario Gregorio Marañón</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Sanz, MD</last_name>
    <phone>034 91 426 5882</phone>
    <email>rsanzruiz@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francisco Fernandez Avilés, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Sanz, MD</last_name>
      <phone>034 91 426 5882</phone>
      <email>rsanzruiz@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>• Francisco Fernandez Aviles, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ricardo Sanz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Fernández-Avilés, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Luis Sánchez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Eugenia Fernández, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique Gutiérrez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esther Pérez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adolfo Villa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Anguita, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>• Juan Carlos Alonso, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>• José Alberto San Román, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier López</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Mota</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roman Arnold</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2012</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>November 17, 2016</last_update_submitted>
  <last_update_submitted_qc>November 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mesenchymal</keyword>
  <keyword>stem cells</keyword>
  <keyword>transendocardial injection</keyword>
  <keyword>dilated idiopathic cardiomyopathy</keyword>
  <keyword>idiopathic cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

